Last checked at 30 Mar 2023 07:00
30 March 2023
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Belluscura PLC
("Belluscura", the "Company" or the "Group")
Change of Auditor
LONDON, U.K. AND PLANO, TX, U.S. (30 March 2023). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen concentrator ("POC") technology, is pleased to announce the appointment of Gerald Edelman LLP as auditor to the company with immediate effect.
Gravita Audit Limited, which was recently formed by the combination of Jeffreys Henry LLP, Arram Berlyn Gardner LLP and Propel, notified the Company that, following a recent review in conjunction with the Institute of Chartered Accountants in England and Wales (the "ICAEW"), it does not have sufficient capacity to satisfy its regulatory requirements in respect of its engagement with the Company and is, therefore, required to resign as auditor with effect from 29 March 2023.
Gravita Audit Limited has confirmed that there are no circumstances connected with their resignation which they consider should be brought to the attention of the Company's members or creditors in accordance with Section 519 of the Companies Act 2006.
Gravita Audit has committed to a smooth handover of their work in progress and the Company is working diligently with Gerald Edelman LLP to complete the audit for the year to 31 December 2022, with its Full Year Results and Report & Accounts expected to be published by 30 June 2023.
For further information please contact:
Belluscura plc | www.belluscura.com | |
Robert Rauker, Chief Executive Officer | via MHP | |
Anthony Dyer, Chief Financial Officer | ||
SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 | |
Neil Baldwin | ||
Dowgate Capital Limited (Broker) | Tel: +44 (0)20 3903 7715 | |
James Serjeant / Nicholas Chambers | ||
MHP (Financial PR and Investor Relations) | Tel: +44 (0)20 3128 8100 | |
Katie Hunt / Pete Lambie / Matthew Taylor | Email: belluscura@mhpgroup.com | |
| ||
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.